Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melanie Furr

Physician Assistant Jackson, MS Physician Assistant

NPI 1538518519 CMS profile 10643318

1325 E Fortification St, Jackson, MS 39202

Open in the dashboard

General payments

$5,371

209 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melanie Furr of Jackson, MS is reported in the CMS Open Payments database as having received $5,371 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,484 58
2024 General $1,216 51
2023 General $1,846 45
2022 General $377 26
2021 General $448 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melanie Furr
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Melanie Furr were reported at $1,484. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Melanie Furr Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $448 $132 $37–$438 $132
2022 $377 $155 $48–$522 $149
2023 $1,846 $167 $52–$557 $160
2024 $1,216 $178 $55–$600 $164
2025 $1,484 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teleflex LLC $1,367 12 payments
  2. Sumitomo Pharma America, Inc. $637 40 payments
  3. Janssen Biotech, Inc. $605 25 payments
  4. AbbVie, Inc. $562 33 payments
  5. Astellas Pharma US Inc $393 8 payments
  6. Dendreon Pharmaceuticals LLC $263 7 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $186 11 payments
  8. Mylan Specialty L.P. $137 7 payments
  9. Axonics Modulation Technologies, Inc. $115 1 payment
  10. Merck Sharp & Dohme Corporation $104 6 payments
  11. Other $1,002 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,464 203 payments
  2. Travel and Lodging $716 3 payments
  3. Education $191 3 payments
Products named General payments · program years 2021–2025
  1. UROLIFT $1,182 9 payments
  2. ERLEADA $605 25 payments
  3. GEMTESA $389 31 payments
  4. PROVENGE $263 7 payments
  5. AKEEGA $243 9 payments
  6. XTANDI $208 5 payments
  7. Xofigo $186 11 payments
  8. Nubeqa $186 11 payments
  9. ORGOVYX $166 6 payments
  10. BOTOX $145 2 payments
  11. Other $2,576 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,919

Median for Physician Assistant: 241

Drug cost

$178,641

Median for Physician Assistant: $4,110

Branded share of claims

29.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 153 $93,006
Myrbetriq Mirabegron Brand 38 $21,885
Ertapenem Ertapenem Sodium Brand 31 $17,302
Elmiron Pentosan Polysulfate Sodium Brand 11 $9,875
Tamsulosin Hcl Generic 522 $7,042
Dutasteride Generic 216 $6,560
Testosterone Generic 11 $3,445
Methenamine Hippurate Generic 66 $2,827
Oxybutynin Chloride Er Oxybutynin Chloride Brand 77 $2,691
Solifenacin Succinate Generic 51 $1,996

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$317,632

Of which drugs: $47,932

Medicare patients

1,353

Average age 75

Services billed

11,813

161 women, 1,192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 36%
Cancer 35%
Diabetes 28%
Atrial fibrillation 20%
Chronic kidney disease 18%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 23 168 $23,560
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 11 1,011 $108

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $192
$192 153 —
XTANDI
  • Astellas Pharma US Inc $138
  • PFIZER INC. $6
$144 — —
ERLEADA
  • Janssen Biotech, Inc. $144
$144 — —
AKEEGA
  • Janssen Biotech, Inc. $113
$113 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $83
  • PFIZER INC. $6
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record